[Federal Register Volume 69, Number 107 (Thursday, June 3, 2004)]
[Notices]
[Pages 31413-31414]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-12464]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I and II and prior to issuing a 
registration under section 10029a) authorizing the importation of such 
a substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with section 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on April 21, 
2004, Research Triangle Institute, Kenneth H. Davis, Jr., Hermann 
Building East Institute Drive, PO Box 12194, Research Triangle Park, 
North Carolina 27709, made application by renewal to the Drug 
Enforcement Administration to be registered as an importer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
 Marihuana (7360)..........................   I
Cocaine (9041).............................   II
------------------------------------------------------------------------

    The firm plans to import small quantities of the listed substances 
for the National Institute of Drug Abuse and other clients.
    Any manufacturer holding or applying for registration as a bulk 
manufacturer of these basic classes of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative (CCD), and must be filed no later than July 6, 
2004.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applications for registration to import basic 
classes of

[[Page 31414]]

any controlled substances in Schedule I or II are and will continue to 
be required to demonstrate to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration that the 
requirements for such registration pursuant to 21 U.S.C. 958(a), 21 
U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are 
satisfied.

    Dated: May 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-12464 Filed 6-2-04; 8:45 am]
BILLING CODE 4410-09-M